Partial
Needs Improvement
Patient Risk:
Moderate
Summary
Several claims are contradicted or not supported because the AI response uses miglustat/miglustat-related safety and assumes a class effect, whereas the provided FDA label excerpts are for GALAFOLD (migalastat) and list different common adverse reactions (headache, nasopharyngitis, UTI, nausea, pyrexia) without diarrhea/weight-change claims.
Category Scores
Accurate Statements
Galafold is the brand name for migalastat.
Drug name and active ingredient in provided label context: GALAFOLD contains migalastat (migalastat hydrochloride) and is an oral capsule formulation.
Miglustat is used to treat adults with Fabry disease who have certain mutations.
The GALAFOLD label indicates treatment for adults with confirmed Fabry disease who have an amenable GLA variant (mutation/variant) based on in vitro assay data.
Miglustat works by helping reduce the buildup of a specific fat (GL-3) in the body.
Label indication notes accelerated approval based on reduction in kidney interstitial capillary cell KIC GL-3 substrate.
Galafold is taken by mouth as prescribed by a clinician.
Label dosage form is oral capsules; dosing is oral.
The exact dosing schedule for Galafold depends on the product labeling and the patient’s medical situation.
Label provides a specific recommended dosing regimen (123 mg every other day) and patient selection requirements; however, this statement is broadly phrased.
Unsupported Statements
Common side effects of miglustat include gastrointestinal tract side effects such as diarrhea.
The provided label excerpts list common adverse reactions as headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia; diarrhea is not listed in the excerpted common adverse reactions.
Common side effects of miglustat include weight changes.
Weight changes are not listed in the provided label excerpted common adverse reactions.
Gastrointestinal side effects and weight changes are class effects associated with miglustat treatment.
The provided label excerpts do not state class effects for gastrointestinal adverse reactions or weight changes.
Safety of miglustat depends on individual health factors, including kidney and liver function and other medications.
The provided excerpts support renal impairment considerations and a caffeine interaction, but do not mention liver function; the statement is broader than the provided label evidence.
Clinicians typically review kidney/liver function and other medications before starting miglustat.
The provided label excerpts discuss renal impairment and caffeine interaction avoidance, but do not explicitly instruct clinicians to review kidney/liver function and other medications.
Fabry disease can be treated with enzyme replacement therapies.
The provided label excerpts for GALAFOLD do not discuss enzyme replacement therapies.
Fabry disease can be treated with other disease-specific options.
The provided label excerpts for GALAFOLD do not discuss alternative Fabry disease treatments.
Contradictions
Low
AI Statement
Common side effects of miglustat include gastrointestinal tract side effects such as diarrhea.
Label Reference
6 ADVERSE REACTIONS (6.1 Clinical Trials Experience) excerpt lists common adverse reactions as headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia; diarrhea is not listed as common in the excerpt.
Low
AI Statement
Common side effects of miglustat include weight changes.
Label Reference
6 ADVERSE REACTIONS (6.1 Clinical Trials Experience) excerpt lists common adverse reactions as headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia; weight changes are not listed as common in the excerpt.
Low
AI Statement
Gastrointestinal side effects and weight changes are class effects associated with miglustat treatment.
Label Reference
6 ADVERSE REACTIONS excerpt does not state class effects; only specific adverse reactions are listed.
Important Omissions
Missed-dose instructions (within 12 hours vs. more than 12 hours) and capsule administration restrictions (swallow whole; do not cut/crush/chew; minimum 4-hour fast with caffeine/food timing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response makes unsupported/incorrect adverse reaction claims (diarrhea and weight changes; class-effect framing) and uses broader safety statements than supported by the provided label excerpts (e.g., liver function and typical clinician review). This could mislead about tolerability and monitoring relative to the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Improvement
Primary Issue
Multiple claims incorrectly attribute miglustat adverse effects/class effects and monitoring considerations that are not supported by the provided GALAFOLD (migalastat) label excerpts.
Suggested Improvement
Rephrase to GALAFOLD/migalastat specifically and align adverse-reaction statements to the label excerpt (headache, nasopharyngitis, UTI, nausea, pyrexia; vomiting added in other phases). Limit interaction statements to caffeine timing (avoid co-administration at least 2 hours before/after) and limit organ-function monitoring claims to what the provided label excerpt supports (renal impairment guidance).